OBJECTIVE: To investigate the synergic effect of propionyl L-carnitine (PLC) plus sildenafil in reducing monocyte oxidative activity and endothelial dysfunction markers in diabetic patients with erectile dysfunction (ED). METHODS: Thirty-two type 2 diabetic patients with ED (according to the International Index of Erectile Function-5 [IIEF-5]) were randomized to receive PLC (2 g/d) alone (n=8) or combined with sildenafil (50 mg/d twice weekly) (n=8), sildenafil alone (50 mg/d twice weekly) (n=8), or placebo (n=8) in a double-blind, fixed-dose study. Monocyte oxidative activity (stimulation index [SI]), intercellular adhesion molecule-1 [ICAM-1], P-selectin, advanced glycation end product (AGE) levels, Doppler sonography (recording peak systolic velocity [PSV]; end diastolic velocity [EDV]; systolic wave time [SWT]; resistive index [RI]), and IIEF score were evaluated before and after 12 wk of treatment; IIEF-5 was evaluated again 4 wk posttreatment. RESULTS: SI was reduced by treatment with PLC alone or combined with sildenafil (p0.05). In patients treated with PLC plus sildenafil, a decrease in ICAM-1, P-selectin, and EDV values was observed compared with patients treated with sildenafil alone (p0.05, p0.01, p0.001, respectively). IIEF-5 improved in all patients treated with PLC plus sildenafil or sildenafil alone (p0.03, p0.05, respectively). Four weeks posttreatment, patients treated with PLC plus sildenafil maintained the improvement of the IIEF-5 compared with patients on sildenafil alone (p=0.05). In patients on PLC treatment (with or without sildenafil), SI was correlated with IIEF-5 (p0.001), glycemia with STW (p0.03), and AGEs with IIEF-5 (p0.01). CONCLUSION: PLC plus sildenafil was more effective in reducing SI and endothelial dysfunction markers in patients with type 2 diabetes and ED

Antioxidant treatment associated to sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study / Morano, Susanna; Mandosi, Elisabetta; Fallarino, Mara; Gatti, Alessandra; Tiberti, Claudio; Sensi, Maurizio; Gandini, Loredana; Buchetti, B; Lenti, Luisa; Jannini, Ea; Lenzi, Andrea. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 52:(2007), pp. 1768-1776. [10.1016/j.eururo.2007.04.042]

Antioxidant treatment associated to sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study

MORANO, Susanna;MANDOSI, ELISABETTA;FALLARINO, Mara;GATTI, ALESSANDRA;TIBERTI, Claudio;SENSI, Maurizio;GANDINI, Loredana;LENTI, Luisa;LENZI, Andrea
2007

Abstract

OBJECTIVE: To investigate the synergic effect of propionyl L-carnitine (PLC) plus sildenafil in reducing monocyte oxidative activity and endothelial dysfunction markers in diabetic patients with erectile dysfunction (ED). METHODS: Thirty-two type 2 diabetic patients with ED (according to the International Index of Erectile Function-5 [IIEF-5]) were randomized to receive PLC (2 g/d) alone (n=8) or combined with sildenafil (50 mg/d twice weekly) (n=8), sildenafil alone (50 mg/d twice weekly) (n=8), or placebo (n=8) in a double-blind, fixed-dose study. Monocyte oxidative activity (stimulation index [SI]), intercellular adhesion molecule-1 [ICAM-1], P-selectin, advanced glycation end product (AGE) levels, Doppler sonography (recording peak systolic velocity [PSV]; end diastolic velocity [EDV]; systolic wave time [SWT]; resistive index [RI]), and IIEF score were evaluated before and after 12 wk of treatment; IIEF-5 was evaluated again 4 wk posttreatment. RESULTS: SI was reduced by treatment with PLC alone or combined with sildenafil (p0.05). In patients treated with PLC plus sildenafil, a decrease in ICAM-1, P-selectin, and EDV values was observed compared with patients treated with sildenafil alone (p0.05, p0.01, p0.001, respectively). IIEF-5 improved in all patients treated with PLC plus sildenafil or sildenafil alone (p0.03, p0.05, respectively). Four weeks posttreatment, patients treated with PLC plus sildenafil maintained the improvement of the IIEF-5 compared with patients on sildenafil alone (p=0.05). In patients on PLC treatment (with or without sildenafil), SI was correlated with IIEF-5 (p0.001), glycemia with STW (p0.03), and AGEs with IIEF-5 (p0.01). CONCLUSION: PLC plus sildenafil was more effective in reducing SI and endothelial dysfunction markers in patients with type 2 diabetes and ED
2007
01 Pubblicazione su rivista::01a Articolo in rivista
Antioxidant treatment associated to sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study / Morano, Susanna; Mandosi, Elisabetta; Fallarino, Mara; Gatti, Alessandra; Tiberti, Claudio; Sensi, Maurizio; Gandini, Loredana; Buchetti, B; Lenti, Luisa; Jannini, Ea; Lenzi, Andrea. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 52:(2007), pp. 1768-1776. [10.1016/j.eururo.2007.04.042]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/359267
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 73
  • ???jsp.display-item.citation.isi??? 65
social impact